Treat-to-Target Guidelines for GCA and PMR The Annals of Rheumatic Disease has published updated multinational, T2T recommendations for the treatment of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR). https://t.co/OQmtqGGNQu https://t.co/eEOTWfdgLI

Prospective study of 490 mod-to-severe psoriasis compared prospectively by exam & US for PsA - 384 w/o arthritis (Silent PSO), 80 non-PSO & 106 w prodromal or active PsA (12.7%). US synovio-enthesitis in 1.8% of controls & 16.1% of silent PSO (p< 0.001) https://t.co/kUdIwLnfYL https://t.co/dgIaOXaJKR

CorEvitas registry data shows H2H comparison of 369 CCP+ abatacept & 475 CCP+ tofacitinib treated patients showed equivalent drug responses (reduced CDAI or PRO's); b/tsDMARD naive pts had numerically better ABA response at 6 mos (P = 0.662) https://t.co/36jr7l2DKm https://t.co/PItYrvMUNV

Granulomatous Myositis? Back to Square One Samuel Ng, MD, presents his poster at RWCS 2023. https://t.co/7dcbUbRe8b https://t.co/9lobNJOkJd

While anifrolumab targets IFN alfa in SLE, its unclear how much IFNa is needed for Rx response. A study of 40 pts shows Rx naive SLE has signif higher serum IFN activity; this is assoc w/ fever, leukopenia, ALE rash and oral ulcers & more organ damage https://t.co/RtI9ulurB1 https://t.co/wMl5DOyGB6

Phase 3 Trials of Baricitinib Disappoint in SL Despite the encouraging phase II trial results of baricitinib in SLE patients, two parallel phase III trials have failed to redemonstrate the efficacy of baricitinib in active SLE. https://t.co/JjouppdG8k https://t.co/SHATPuTIiP

Korean study Neonatal/maternal outcomes w/ NSAIDs. 1.8 million pregn assoc w/ early preg NSAIDs exposure - incr risks for major congenital malformations (adjRR 1.14), low birth Wt (1.29) & maternal oligohydramnios (1.09); higher w/ COX-2i or NSAIDs>10d https://t.co/SaRrVOHOt9 https://t.co/b2YqUh91fK

FDA has approved sarilumab (Kevzara) for the treatment of polymyalgia rheumatica (PMR) in adult patients who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. Approval is based on Phase 3 SAPHYR study https://t.co/kA9pTauvDP https://t.co/GGlyvQcyat

Check out last week's podcast--we discuss interesting data on the risk of arthritis comes from a large NHANES study. https://t.co/w5TNhH7a2f https://t.co/bkKDoWA0ft

Is it Lupus? https://t.co/PIIFeeHVMf https://t.co/5fUfAAyFul

An Alternative Pain Protocol Following Knee Replacement Surgery A study reports that a novel surgical pain management strategy following total knee arthroplasty (TKA), or total knee replacement, provided pain relief without opioids. https://t.co/OMQ4Tjl8Yv https://t.co/Hu59WJohcN

We're less than 3 weeks out from RheumNow Live. Are you coming? We'll be hosting a variety of topic panels, including one focused on Spondyloarthritis Innovations. Join us! https://t.co/AOJGKTss7Q https://t.co/7nCdgwO6Zh